Early-stage multi-marker assay development and validation for esophageal adenocarcinoma
10.3969/j.issn.1000-484X.2025.04.033
- VernacularTitle:食管腺癌早期多种标志物检测试剂的开发与验证
- Author:
Nuobei ZHAO-LIU
1
;
Xiaomei ZHANG
;
Meng XU
;
Yan JIA
;
Hao CHEN
;
Jing YANG
;
Xiaobo YU
Author Information
1. 河北大学化学与材料科学学院,保定 071002;医学蛋白质组学全国重点实验室,北京蛋白质组研究中心,国家蛋白质科学中心-北京(凤凰中心),军事科学院军事医学研究院生命组学研究所,北京 102206
- Publication Type:Journal Article
- Keywords:
Esophageal adenocarcinoma;
Liquid phase chip;
Early protein biomarkers;
In vitro diagnostics
- From:
Chinese Journal of Immunology
2025;41(4):972-978
- CountryChina
- Language:Chinese
-
Abstract:
Objective:Given the insufficiency of current clinical biomarkers for early diagnosis of esophageal adenocarcinoma(EAC),this study developed a panel of serum protein biomarker assays using liquid-phase chip technology and preliminarily validated the detection capabilities of these markers for EAC.Methods:Collected serum samples from 48 patients with EAC and 33 age-matched healthy controls(HC).The levels of squamous cell carcinoma antigen(SCCA),human cytokeratin 19 fragment(Cyfra21-1),hepatocyte growth factor(HGF)and IL-8 in serum were analyzed by liquid chip technology.The diagnostic efficacy of a single indicator and a combination of four indicators were evaluated by receiver operation characteristic(ROC)curve.Results:The detection ranges of SCCA,Cyfra21-1,HGF and IL-8 were 0.24～1 000 ng/ml,45.72～100 000 pg/ml,21.95～16 000 pg/ml,and 0.61～10 000 pg/ml,respectively.The liquid chip technology shows a strong correlation with clinical chemiluminescence immunoassay(r=0.949 4,P<0.000 1)and ELISA technology(r=0.955 1,P<0.000 1).Compared to the HC group,serum levels of SCCA and HGF were signifi-cantly elevated in the EAC group(P<0.01),IL-8 was significantly decreased(P<0.05),while Cyfra21-1 shows no significant difference(P>0.05).In the early EAC group,serum HGF was significantly higher than in the HC group(P<0.01).ROC curve analysis shows that among individual markers,HGF exhibits the best diagnostic efficacy for early EAC with an area under the curve(AUC)of 0.761,while the AUC for the combination of the four biomarkers was 0.857,both superior to the clinical biomarkers SCCA(AUC=0.604)and Cyfra21-1(AUC=0.515).Conclusion:Liquid chip technology is used to jointly detect SCCA,Cyfra21-1,HGF,and IL-8 in human serum.In the early diagnosis of EAC,the diagnostic efficacy of the combined use of these four biomarkers is superior to that of the commonly used clinical tumor markers SCCA and Cyfra21-1.This advantage stems from the high throughput and high sensitivity characteristics of liquid-phase chip technology.Consequently,this combined detection method holds significant clinical application and is expected to provide a more accurate and reliable tool for the early diagnosis of EAC.
